News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Launches collaborative centre for translational research in head and neck cancer
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Subscribe To Our Newsletter & Stay Updated
